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Abstract
The pathological hallmarks of Parkinson’s disease (PD) are degeneration of dopamine (DA) neurons of the substantia nigra
(SN) and the presence of alpha-synuclein (a-syn)-rich Lewy bodies in DA cells that remain. To model these aspects of the
disease, we previously showed that high titer (5.1610exp12 gp/ml) AAV1/2 driven expression of A53T a-syn in the SN of
rats caused nigrostriatal pathology including a loss of DA neurons, but also with toxicity in the GFP control group. In the
current study, we evaluate the effects of two lower titers by dilution of the vector (1:3 [1.7610exp12] and 1:10
[5.1610exp11]) to define a concentration that produced pathology specific for a-syn. In GFP and empty vector groups there
were no behavioural or post-mortem changes at 3 or 6 weeks post-administration at either vector dose. Dilution of the
AAV1/2 A53T a-syn (1:3) produced significant paw use asymmetry, reductions in striatal tyrosine hydroxylase (TH), and
increases in DA turnover at 3 weeks in the absence of overt pathology. By 6 weeks greater evidence of pathology was
observed and included, reductions in SN DA neurons, striatal DA, TH and DA-transporter, along with a sustained behavioural
deficit. In contrast, the 1:10 AAV1/2 A53T a-syn treated animals showed normalization between 3 and 6 weeks in paw use
asymmetry, reductions in striatal TH, and increased DA turnover. Progression of dopaminergic deficits using the 1:3 titer of
AAV1/2 A53Ta-syn provides a platform for evaluating treatments directed at preventing and/or reversing synucleinopathy.
Use of the 1:10 titer of AAV1/2 A53T a-syn provides an opportunity to study mechanisms of endogenous compensation.
Furthermore, these data highlight the need to characterize the titer of vector being utilized, when using AAV to express
pathogenic proteins and model disease process, to avoid producing non-specific effects.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized clinically by rigidity, slowness of movement and
tremor and neuropathologically by a severe loss of dopamine (DA)
neurons of the substantia nigra (SN) and with Lewy bodies in the
majority of those that remain. Lewy bodies are proteinaceous intra-
neuronal inclusions that are largely composed of alpha-synuclein (a-
syn) and their presence is often necessary for the final diagnosis of
PD [1,2,3,4]. The normal function of a-syn has yet to be fully
characterized; however, mounting evidence supports its role as a
synaptic protein involved with vesicular release of neurotransmitters
(including DA) [5,6,7,8,9,10,11,12]. Over-expression studies have
also implicated a normal physiological role for a-syn in axonal
transport [13] and in mechanisms of autophagy [14,15,16,17].
Triplication, duplication or mutations (A53T, A30P, E46K) in
the gene encoding a-syn, SNCA1, produce familial forms of PD
[18,19,20,21,22]. Not long after these discoveries, transgenic mice
[16,23,24,25,26,27] and viral vector rodent and primate models
over-expressing a-syn were reported [13,28,29,30,31,32,33].
While these transgenic mice have proven useful in advancing
understanding of how high levels of a-syn interfere with normal
cellular function, they fail to model the nigrostriatal pathology and
basal ganglia-based motor features of PD. Viral vector models
were able to overcome this by targeting the basal ganglia directly
through injection into the SN and have been shown repeatedly to
produce a progressive nigrostriatal degeneration along with motor
impairments. However, to date viral vector-based models show
variability in degrees of pathology and onset to expression of
behavioural impairments [13,30,31,32,34].
In an effort to develop a new viral vector-based model of PD
that could consistently deliver nigrostriatal pathology and relevant
behavioural deficits in a relatively short period of time (more
amendable to in vivo drug evaluation) we have previously used a
high titer formulation of chimeric AAV1/2 human A53T a-syn
(5.1610
12 gp/ml) and examined tissues 3 weeks after injection into
the SN [35]. We found that overexpression of A53T a-syn
produced insoluble aggregates along with dopaminergic degener-
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17698ation. However, in control studies where the same vector, at the
same titer, was used to express GFP we found evidence of SN
neuronal loss. Although this AAV1/2 GFP-induced cell loss was
significantly less than with the AAV1/2 A53T a-syn cases, it
clearly showed that we could not attribute all the effects to A53T
a-syn per se. Since the empty vector controls showed no evidence of
neurodegeneration we concluded that expression of a protein from
this high concentration of vector was sufficiently burdensome to be
toxic to SN DA neurons.
In the current study, we have formulated the same AAV1/2
vectors to assess whether lower titer preparations might produce
degeneration specific to A53T a-syn. We report that a 1:3 dilution
(1.7610
12 gp/ml) produces a progressive degeneration along with
a behavioural impairment that occurs over the course of 6 weeks,
while a 1:10 dilution (5.1610
11 gp/ml) produces signs of
dopaminergic dysfunction and a behavioural impairment at 3
weeks that are shown to reverse by 6 weeks. In both conditions, no
sign of GFP toxicity is observed.
Results
Co-localization and forebrain expression of proteins
delivered by AAV1/2 vectors
Delivery of human A53T a-syn or GFP using AAV1/2 vectors
resulted in expression in .95% of dopamine (DA) neurons within
the anatomical boundaries of the substantia nigra (SN). Figure 1
shows that both concentrations of viral vector produced similar
degrees of co-localization with DA neurons (using tyrosine
hydroxylase as a marker; TH) of the SN by 3 weeks, which was
maintained through 6 weeks, indicating that the subsequent results
are not due to the number of DA neurons being infected by
AAV1/2 particles, but rather the levels of expression within the
transduced neurons.
Accumulations of human a-syn were observed in transfected SN
DA neurons and co-expressed with TH (Figure 1E). Expression of
a-syn or GFP in the striatum was prevalent, by 3 weeks,
throughout its anatomical boundaries regardless of the dose of
AAV1/2 used (Figure 1K). Transgene expression in the SN and
striatum remained at similar levels 6 weeks post vector injection
(data not shown).
Forelimb use in the cylinder test
Animals that received either the 1:10 (F2,20=5.55, P=0.012) or
1:3 (F2,21=36.05, P,0.0001) concentration of AAV1/2 A53T a-
syn showed a deficit in the use of their paw contralateral to the side
of vector injection 3 weeks post surgery compared to GFP (1:10,
P,0.05; 1:3, P,0.001) and empty vector (EV) (1:10, P,0.05; 1:3,
P,0.001) controls. This was represented by a 39% and a 57%
increase forelimb use asymmetry in 1:10 and 1:3 AAV1/2 a-syn
injected rats, respectively, compared to EV controls. Six weeks
Figure 1. Transgene expression in the substantia nigra and striatum. AAV1/2 delivered to the substantia nigra (SN) as two concentrations
(1:3, 1.7610
12 gp/ml and 1:10, 5.1610
11 gp/ml) resulted in expression of human a-synuclein (A–E) or GFP (F–J) in the vast majority SN TH-ir neurons
and transport of transgenes to the striatum (K). Confocal imaging and orthogonal views of collected Z-stacks confirmed that a-synuclein accumulated
(white arrows in G) within SN TH-ir neurons (G). Scale bar in panel A is 200 mm and applies to panels A–D, F–I. Scale bar in panel G is 20 mm and
applies to panels G and J. Scale bar in panel K is 1 mm.
doi:10.1371/journal.pone.0017698.g001
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A53T a-syn showed a recovery in function compared to controls
(P.0.05), while the animals in the 1:3 administered group
demonstrated a persistent asymmetry in forelimb paw use
(F2,20=9.6, P=0.001; post-hoc, cf. GFP or EV, both P,0.01).
See Figure 2.
Cell number in the substantia nigra
Three weeks following delivery of vectors coding for GFP, or a-
syn and an empty vector, no difference in the number of TH-
immunoreactive (ir) cells in the SN was evident (P.0.05). In
contrast, at the 6 week timepoint, there was a significant difference
in the number of TH-ir cells in the SN when compared across all
three groups in the 1:3 condition (Figure 3A–C) (F2,14=4.37,
P,0.05). Post-hoc analysis revealed that animals that received the
1:3 AAV1/2 A53T a-syn showed a significant decrease (by 28%)
in TH-ir cells compared to EV controls (P,0.05) and no
significant difference to GFP controls (P.0.05). There were no
significant differences among conditions in the 1:10 dilution at the
6 week timepoint (P.0.05). See Figure 3.
Expression of tyrosine hydroxylase and axonal
morphology of nigrostriatal fibers in the striatum
Expression of TH in the striatum, as measured by optical
density, was shown to be significantly reduced at the 3 week
timepoint in both the 1:3 (by 7% from EV) (F2,14=4.77, P,0.05;
post-hoc, c.f. EV, P,0.05) and 1:10 A53T a-syn conditions (by 13%
from EV) (F2,14=8.93, P,0.01; post-hoc, c.f. EV, P,0.05, c.f. GFP,
P,0.01) (Figure 4A,C). In contrast, by 6 weeks, the expression of
TH normalized in the 1:10 condition (P.0.05) compared to EV
and GFP controls and was shown to be further reduced in the 1:3
condition (24.5% from EV) (F2,14=6.57, P,0.01; post-hoc, c.f. GFP
or EV, both P,0.05) (Figure 4B,D).
The reduction in striatal TH expression was accompanied by
the appearance of abnormal axon morphology. Using antibodies
directed against human a-syn, axonal architecture in the
striatum was examined. The presence of dystrophic neurites
were evident in the 1:3 AAV1/2 A53T a-syn injected animals by
3 weeks and were shown to be more severe or pronounced after
6 weeks (Figure 5A,B), while the degree of abnormal axonal
morphology in the 1:10 AAV1/2 A53T a-syn injected animals
was minimal or absent at both the 3 and 6 week timepoints
(Figure 5C,D).
Dopamine transporter and neurochemistry in the
striatum
Delivery of human A53T a-syn (1:3 dilution) to the SN
produced a 31% increase in striatal DAT binding, measured by
autoradiography, 3 weeks post injection (F2,15=4.94, P=0.02;
post-hoc, c.f. EV, P,0.05). However, at the 6 week timepoint DAT
binding was shown to be significantly reduced by 48% compared
to levels in the EV condition (F2,18=5.61, P=0.013; post-hoc, c.f.
EV or GFP, both P,0.05) (Figure 6A). No significant alterations
in DAT binding were seen in the 1:10 A53T a-syn or in either
concentration of GFP.
Using HPLC to quantify total DA levels and its metabolites in
the striatum we found that expression of human A53T a-syn
produced significant alterations. Firstly, DA was unchanged in
both the 1:3 and 1:10 dilutions at the 3 week timepoint, however
at 6 weeks DA was significantly reduced by 43% in the 1:3
condition (F2,21=9.55, P,0.01; post-hoc, c.f. EV or GFP, both
P,0.01) and remained unchanged in the 1:10 condition
(Figure 6B). The turnover of DA as measured by the ratio,
HVA/DA, was significantly increased by 26% in the 1:10 dilution
(F2,20=5.04, P,0.05; post-hoc, c.f. EV, P,0.05) and by 22% in the
1:3 dilution at 3 weeks compared to EV controls (F2,21=8.49,
P=0.002; post-hoc, c.f. EV, P,0.05; c.f. GFP, P,0.01). At the 6
week timepoint, DA turnover was further increased in the 1:3
condition compared to EV controls (now a 58% increase)
(F2,19=10.53, P,0.001; post-hoc, c.f. EV, P,0.001 or c.f. GFP
P,0.05), while in contrast DA turnover was restored to control
levels (GFP and EV) in the 1:10 condition (Figure 6C). Neither the
GFP nor EV groups had any impact on striatal DA neurochem-
istry as compared to their respective contralateral side or when
compared to each other.
Discussion
In the vast majority of Parkinson’s disease cases, irrespective of
etiology, is the presence of intraneuronal Lewy bodies composed
primarily of alpha-synuclein (a-syn) within the substantia nigra
(SN). In the current study, we showed that delivery of human
A53T a-syn to the rat SN using AAV1/2 results in a behavioural
deficit along with key elements of nigro-striatal degeneration
associated with PD and in a time- and dose-dependent manner.
Previously we have shown that delivery of this same vector,
albeit at a higher titer, 5.1610
12 gp/ml, produced a loss of SN
TH-ir and NeuN-ir cells within 3 weeks [35]. In that study, a-syn
Figure 2. Forelimb asymmetry in the cylinder test. Three weeks following injection of AAV1/2 A53T a-synuclein a significant asymmetry in
forelimb use is present in rats exposed to either titer of vector (1:10, 5.1610
11 gp/ml [panel A] or 1:3, 1.7610
12 gp/ml [panel B]). At six weeks however
the rats injected with the 1:10 dilution recovered on this test (A), while the rats injected with the 1:3 dilution continued to show a behavioural
impairment (B). *
,**
,*** c.f. empty vector, P,0.05, 0.01, and 0.001 respectively;
#,##,### c.f. GFP, P,0.05, 0.01, and 0.001 respectively.
doi:10.1371/journal.pone.0017698.g002
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as evidencedbyresistance to proteinase K digestion. Accompanying
this were reductions in TH-ir and DAT in the striatum and a
marked presence of dystrophic neurites compared to empty vector
controls. However, in that previous study, we showed that high titer
AAV1/2 GFP also produced, though to a lesser extent, degener-
ation in the SN (loss of TH-ir and NeuN-ir cells) without signs of
pathology at the level of the striatum [35]. In that study, human
A53T a-syn could not be solely accountable for the pathology
produced, suggesting that there likely exists a toxic effect of
overloading SN TH-ir neurons with a protein. In light of these data,
we embarked on the current study to examine the effects of 2 lower
titers of the AAV1/2 to define a concentration of viral particles that
produced nigro-striatal pathology that could be attributed to human
A53T a-syn, and not to an effect of protein overload.
We report that a dilution of 1:3 (final titer of 1.7610
12 gp/ml)
achieved this goal although following a longer time course than the
undiluted vector stock. Thus, 3 weeks following SN injection of
AAV1/2 we found that a-syn accumulated in SN TH-ir neurons
in the absence of cell loss and a moderate degree of dystrophic
axons were apparent in the striatum. Furthermore, striatal TH was
significantly reduced, dopamine turnover (HVA/DA) and dopa-
mine transporter (DAT) were increased and an asymmetry in
forelimb paw use was present in the cylinder test. However, six
weeks following vector injection this model shows mounting
evidence of nigrostriatal pathology, including further reductions in
striatal TH, a more severe presence of dystrophic neurites, a
reduction in striatal DA and DAT, a greater increase in DA
turnover, and a sustained behavioural deficit compared to both
empty vector and AAV1/2 GFP control groups. On the measure
of SN TH-ir cell counts however, AAV1/2 A53T a-syn was only
significantly different from empty vector controls and not to
AAV1/2 GFP (AAV1/2 GFP injected rats were not significantly
different from those that received the empty vector). Overall, these
data are consistent with those reported previously [13,30,32,33,
35,36]. Thus, overexpression of a-syn by AAV injected into the
SN consistently has produced signs of dopaminergic dysfunction
along the nigrostriatal path. The time it takes (3–16 weeks) and the
severity of dopaminergic deficits produced varies (cell loss ranging
from 30–60%) between studies and likely depends on the
combination of serotypes, promoters and viral titers utilized. In
the current study we show that 28% of TH-ir SN neurons are lost
compared to empty vector controls measured 6 weeks post AAV1/
2 injection. What has been less consistent is the expression of
behavioural deficits in these models and the apparent reliance on
significant cell death as an underlying factor. In the current study,
a clear behavioural deficit (cylinder test) is observed by 3 weeks
post AAV1/2 A53T a-syn injection. Of interest, the first
appearance of a behavioural deficit, at 3 weeks, was without the
requisite of cell death. Such a finding has not previously been
reported; indeed previous studies report cell loss without a
behavioural deficit [13,32,34]. This finding has been replicated
in our hands across experiments within and between vector
preparations (data not shown).
Figure 3. Dopamine neuron loss in the substantia nigra. Stereological counting of TH-ir neurons in the substantia nigra (SN) showed that
AAV1/2 A53T a-synuclein (1:3, 1.7610
12 gp/ml) reduces the number of dopamine neurons 6 weeks following intra-nigral injection, while
quantification at 3 weeks or when using the 1:10 dilution (5.1610
11 gp/ml) at either timepoint, showed no evidence of neuron loss. Panels A, B and C
represent significant comparisons found in the AAV1/2 [1:3] graphs. Scale bar in panel A is 1000 mm. * P,0.05 c.f. empty vector.
doi:10.1371/journal.pone.0017698.g003
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impairment at 3 weeks in the absence of a reduction in striatal DA
levels or SN cell numbers, while in the presence of moderate
dystrophic axonal morphology and a modest reduction in striatal
TH, in animals that received the 1:3 dilution of the AAV1/2
A53T a-syn. In traditional toxin based rodent models of PD (6-
OHDA and MPTP) motor deficits are not encountered until at
least 50% of the SN DA neurons are lost and with that a
significant reduction in striatal DA (,80%). This finding further
suggests that a-syn plays a significant role at the synaptic terminal,
involved with DA and its handling at the level of the vesicles
antecedent to overt pathology. It has recently been reported that
a-syn participates in managing the release pool of vesicles in DA
terminals and that levels of synaptic proteins VAMP-2 and
synapsin-1 are significantly altered after exposure to increasing
levels of a-syn [12]. Although not directly tested in our current
study, it is possible that in our model, A53T a-syn acts to interfere
with vesicular release of DA and this underlies the behavioural
phenotype. In this scenario, DA levels would appear normal (as
seen with whole tissue HPLC), although DA release necessary for
normal motor behaviour might be compromised. In order to begin
to address this hypothesis, future studies will need to be conducted
that, for example, quantified DA release (e.g. in vivo microdialysis)
and/or measured a panel of synaptic proteins involved in vesicle
regulation. Evidence that a-syn inhibits neurotransmitter release
has been recently reported [10,37]. In Chung et al (2009) it was
reported, in rats, that AAV2 overexpression of A53T a-syn
produced a slow progressive pathology that was related to
alterations in axonal transport, synaptic proteins, and induction
of neuroinflammation [13]. These data further support the
contention that overexpression of a-syn produces a phase of
axonal or terminal stress prior to overt degeneration that can have
significant functional consequences.
Of additional interest is the finding that DAT binding, in rats
injected with 1:3 AAV1/2 A53T a-syn, was significantly elevated
(31%) 3 weeks post injection and prior to signs of degeneration. At
this timepoint there was also a reduction in striatal TH, an
increase in DA turnover, and a deficit in contralateral paw use.
Elevated DAT levels may represent an attempted compensatory
response aimed at maintaining normal levels of DAT in light of
reduced DA terminals. This response however fails to normalize
terminal function and potentially contributes to the motor deficit
observed (i.e. excessive DAT may contribute to reduced synaptic
DA and result in motor dysfunction). In support of this hypothesis,
transgenic mice that overexpress DAT (by 30%) have been shown
to release 40% less DA and uptake it at a rate 50% greater
compared to controls [38]. Taken together, if a-syn interferes with
DA release [10,12] and initial DA fibre loss results in above
normal DAT levels (seen here), the net result could be less synaptic
DA available for transmission and thereby abnormal motor
Figure 4. Reduced striatal tyrosine hydroxylase expression in AAV1/2 A53T a-synuclein injected rats. Three weeks following intra-nigral
injection of both titers of AAV1/2 A53T a-syn (1:3, 1.7610
12 gp/ml and 1:10, 5.1610
11 gp/ml) there was a significant reduction in the expression of
striatal tyrosine hydroxylase (TH). By six weeks the reduction in striatal TH had recovered in the 1:10 condition (D), while in the 1:3 condition, a greater
loss in TH was observed (B). Panels A, B, C and D represent significant comparisons found in the graphs. * P,0.05 c.f. empty vector,
# c.f. GFP.
doi:10.1371/journal.pone.0017698.g004
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timepoint, however, fibers are increasingly lost (measured by TH
and DAT) and the prototypical nigrostriatal pathology becomes
apparent (DA neuron loss in SN and reduced striatal DA).
Therefore, at the 3 week timepoint, it is likely that the behavioural
deficits are a result of A53T a-syn-induced dysfunction of a
Figure 5. Dystrophic axon morphology in rats injected with AAV1/2 A53T a-synuclein. Delivery of AAV1/2 A53T alpha-synuclein (1:3,
1.7610
12 gp/ml) to the substantia nigra produces dystrophic and bulging neurites in the striatum 3 and 6 weeks later with increasing severity (A,B).
Injection of the 1:10 dilution (1:10, 5.1610
11 gp/ml) of AAV1/2 AAV1/2 A53T a-syn also showed signs of abnormal axonal architecture, although not
to the same degree (C,D). Arrows point to evidence of human alpha-synuclein positive dystrophic neurites; scale bar is 50 mm.
doi:10.1371/journal.pone.0017698.g005
Figure 6. Striatal changes in dopamine transporter and neurochemistry following intra-nigral injection of AAV1/2 A53T a-
synuclein. Three weeks post AAV1/2 A53T a-syn injection of the 1:3 dilution there was a significant rise in dopamine transporter (DAT) followed 3
weeks later by a significant reduction (A). No changes in striatal DAT was observed using the 1:10 dilution of AAV1/2 A53T a-syn at either timepoint
(A). Dopamine loss was seen only in the 1:3 dilution of AAV1/2 A53T a-syn and only after 6 weeks of exposure (B). Dopamine turnover (HVA/DA) was
significantly elevated in both the 1:3 and 1:10 AAV1/2 A53T a-syn conditions, 3weeks post vector injection. By 6 weeks however, DA turnover had
returned to normal in the 1:10 AAV1/2 A53T a-syn group and had increased further in the 1:3 AAV1/2 A53T a-syn group (C). *
,** c.f. empty vector,
P,0.05 and 0.01, respectively;
#,## c.f. GFP, P,0.05 and 0.01, respectively.
doi:10.1371/journal.pone.0017698.g006
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weeks, deficits are a combination of an ongoing A53T a-syn
induced impairment of DA function and frank degeneration of the
nigrostriatal system. It is not known whether the behavioural
deficits produced here are reversible by administration of L-
DOPA (L-3,4-dihydroxyphenylalanine) or a DA agonist. Future
studies will investigate this.
The 1:3 dilution used here we consider to be a model of
progressive degeneration. We showed that, over time, A53T a-syn
resulted in (1) decreasing levels of striatal TH, (2) increasing rates
of DA turnover, (3) progressively more severe dystrophic axonal
architecture, (4) a rise and subsequent fall in striatal DAT, (5) a loss
of TH-ir cells in the SN and (6) a sustained behavioural
impairment. This implementation of the model is ideally suited
for studying potential neuroprotective, disease modifying or
neurorestorative treatments. For example, delivery of a treatment
close in time to the delivery of the viral vector, could evaluate
potential to prevent formation of a-syn aggregates, measured at 3
weeks, and subsequently verify that this resulted in neuroprotec-
tion, measured at 6 weeks when degeneration is expected in
controls. In a disease modifying paradigm, one could commence
delivery of the treatment at 3 weeks, a timepoint when there is
aggregated a-syn in the absence of cell loss, and evaluate its
efficacy 3 weeks later and directly correlate outcome with levels of
a-syn. This paradigm in particular will allow for an evaluation of
treatments to target various species of a-syn. Thirdly, a
neurorestorative design can be envisaged, whereby the treatment
is administered after degeneration had already begun, i.e. at the 6
week timepoint and evaluate outcome several weeks later.
The study also defined a model that produced signs of neuronal
stress that over time self-corrected. Thus, delivery of the 1:10 titer,
5.1610
11 gp/ml AAV1/2 A53T a-syn, resulted in a behavioural
deficit, an increase in DA turnover, and a reduction in striatal
levels of TH when measured at 3 weeks. By 6 weeks, each of these
measures had returned to normal. Delivery of this dose of A53T a-
syn via this particular AAV1/2 is thus a model to study
endogenous compensation and could prove promising in discov-
ering targets to modify disease course.
In conclusion, we have developed a viral vector rat model of
Parkinson’s disease, based on overexpression of human A53T a-
syn that is suitably titered to produce a specific and progressive
degeneration of the nigrostriatal system. Two models emerged
from this work, one that is progressively degenerative and another
that demonstrates endogenous compensation. The former will be
used to investigate new therapeutics directly targeting alpha-
synuclein and its associated pathology and the latter to understand
the mechanisms by which compensation can occur which has
potential to generate new therapeutic targets.
Materials and Methods
Animals and vector delivery
Using standard stereotaxic procedures, 160 female Sprague
Dawley rats (,280 g, Charles River) were injected intranigrally
with either empty AAV1/2 vector, AAV1/2 expressing GFP, or
AAV1/2 expressing human A53T alpha-synuclein, under isoflur-
ane/oxygen anesthesia. In each case, a single 2 ml injection of viral
vector was delivered to the SN at a rate of 0.2 ml/min according to
the following coordinates from bregma: AP, 25.2 mm; ML,
22.0 mm; DV, 27.5 mm (from skull at bregma) using a
microinjector (Stoelting, Kiel, WI) and according to the atlas of
Paxinos and Watson [39]. The AAV1/2 stock concentration for
each vector was 5.1610
12 genomic particles (gp)/ml. Two
concentrations of this stock, for both AAV1/2 GFP and AAV1/
2 A53T a-syn were used, 1.7610
12 gp/ml (1:3 dilution) and
5.1610
11 gp/ml (1:10 dilution). Animals were housed in pairs in a
temperature controlled environment (20uC), kept on regular 12 hr
light/dark cycle (lights on 0630) and allowed food and water ad
libitum. All procedures were conducted under an approved IACUC
(University Health Network, protocol 1738.6) in accordance with
guidelines and regulations set by the Canadian Council on Animal
Care.
Vectors
Adeno associated vectors (AAV) of a 1/2 serotype were
designed such that expression was driven by a chicken beta actin
(CBA) promoter hybridized with the cytomegalovirus (CMV)
immediate early enhancer sequence. In addition, a woodchuck
post-transcriptional regulatory element (WPRE) and a bovine
growth hormone polyadenylation sequence (bGH-polyA) were
incorporated to further enhance transcription following transduc-
tion. AAV1/2 is a chimeric vector where the capsid expresses
AAV1 and AAV2 serotype proteins in a 1:1 ratio and uses the
inverted terminal repeats (ITRs) from AAV2 according to the
following scheme: CMV/CBA promoter––human A53T alpha-
synuclein or GFP––WPRE-bGH-polyA––ITR [40]. The vectors
were produced by GeneDetect Ltd., Auckland, New Zealand.
Viral titers were determined by quantitative PCR (Applied
Biosystems 7900 QPCR) with primers directed to the WPRE
region, thus representing the number of functional physical
particles of AAV in the solution containing the genome to be
delivered. Full details of vector design can be found in Koprich
et al., 2010 [35].
Cylinder Test
Three and six weeks following AAV1/2 injection, spontaneous
forepaw use was evaluated using the cylinder test. Briefly, rats with
their right paws marked black were placed into a glass cylinder in
front of 2 mirrors and they were video recorded. Videos were
scored post-hoc by an observer blinded to the treatment conditions.
For each rearing by the animal it was recorded whether it used its
left or right forepaw to touch the inner surface of the glass cylinder.
Scoring was conducted over a period of 6 min. A minimum of 20
total touches was considered acceptable for inclusion in the
analysis. The final data are presented as percent asymmetry
(disparity between left [contralateral to the injection] and right
paw use [ipsilateral to the lesion]), which was derived from the
following equation according to Wishaw and Kolb (2005): [(%
right paw use)2(% left paw use)/(% right paw use)+(% left paw
use)] * 100 [41].
Post-mortem measures
Immunohistochemistry. Three and six weeks after AAV1/
2 injection, animals were administered an overdose of
pentobarbital (1.0 ml of 240 mg/ml, i.p.) and killed by
exsanguination by transcardial perfusion with saline followed by
4% paraformaldehyde. Brains were then removed and processed
for immuno-labeling. Brains were sectioned frozen in the coronal
plane at a thickness of 40 mm on a sliding microtome (Leica
Microsystems Inc., Richmond Hill, ON) and 6 series of sections
were stored in cryoprotectant (30% glycerol, 30% ethoxyethanol,
40% PBS). A single series of sections was processed for
visualization of tyrosine hydroxylase (TH) via the biotin-labelled
antibody procedure. Briefly, following several washes in a PBS
solution containing 0.2% Triton X-100 (PBS-T), endogenous
peroxidase was quenched in a 3% hydrogen peroxide solution and
background staining was then inhibited in a 10% normal goat
serum/2% bovine serum albumin solution. Tissue was then
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antibody (1:1000, Pel-Freez, Rogers, AR), mouse anti-NeuN
antibody (1:200, Millipore, Billerica, MA). After three washes in
PBS-T, sections were sequentially incubated in biotinylated goat
anti-rabbit or mouse IgG (1:300; Vector, Burlingame, CA) for 1 h
and the Elite avidin-biotin complex (ABC Kits; Vector,
Burlingame, CA) for 1 h separated by three washes in PBS.
Immunostaining was visualized following a reaction with 3,3-
diaminobenzidine (Vector, Burlingame, CA). Sections were then
mounted on glass slides, allowed to dry, dipped into dH20,
dehydrated through graded alcohols (70%, 95%, 100%), cleared
in xylenes, and coverslipped with DPX mounting medium
(Electron Microscopy Sciences, Hatfield, PA).
In the striatum, the degree of TH expression was assessed using
optical density (OD) measurements of immuno-labelled tissue
(ImageJ, version 1.43u). Images were captured under uniform light
conditions using a slide scanner (Myer Instruments, Houston,TX).
Three anatomical levels were assessed (pre-commissural, commis-
sural, and post-commissural) and for each level the contralateral
striatum was also assessed. Final values represent the average of
the 3 anatomical levels taken as a percentage of the average of
each corresponding contralateral level.
Immunofluorescence (Confocal microscopy, Zeiss Axioplan
with LSM510META) to reveal TH (1:1000, Pel-Freez, Rogers,
AR) and human alpha-synuclein (1:500, Zymed, San Francisco,
CA) or GFP (1:2000, Abcam, Cambridge, MA) simultaneously
was conducted. Images were taken throughout the Z-axis to
confirm co-localization of a-syn and GFP within individual TH
neurons.
Stereology. TH stained sections of the SN were used for
stereological estimation of dopamine neuron numbers using
optical fractionator from the Stereo Investigator software
package (v. 7, MBF Biosciences, Williston, VT). The user was
blinded to group assignment by coded slides. Nine sections
spanning the entire anterior/posterior extent of the SN, each
separated by 240 mm (1/6 series), were used for counting. All TH-
ir neurons of the SN (pars compacta and pars reticulata) were
included within each contour, of each section. Parameters used for
TH stereological counting were grid size, 300 mm6300 mm;
counting frame, 80 mm680 mm, and 2 mm guard zones. Tissue
thickness was determined by the user at each counting site. All
final values represent estimated total by number weighted section thickness
and were only included if their Gunderson coefficient of error
(m=1) was less than 0.09.
Autoradiography. The levels of striatal DAT were assessed
by [
125I]-RTI-121 binding autoradiography in sections prepared
from fresh-frozen tissue. Briefly, thawed slides were placed in
binding buffer (2615 min, room temperature) containing 50 mM
Tris, 120 mM NaCl and 5 mM KCl. Sections were then placed in
the same buffer containing 50 pM [
125I]-RTI-121 (Perkin-Elmer,
specific activity 2200 Ci/mmol) for 120 min at 25uC to determine
total binding. Non-specific binding was defined as that observed in
the presence of 100 mM GBR 12909 (Tocris Bioscience). All slides
were then washed (4615 min) in ice-cold binding buffer, rinsed in
ice-cold distilled water and air-dried. Together with [
125I]-
microscale standards (Amersham) slides were then apposed to
autoradiographic film (Kodak) and left for 2 days at 4uC before
developing. Autoradiograms were analysed using MCID software
(Image Research Inc, Ontario, Canada). Densitometric analysis of
3 striata from each animal was carried out whereby a reference
curve of c.p.m. versus optical density was calculated from b-
emitting [
14C] micro-scale standards and used to quantify the
intensity of signal as nCi/g. Background intensity was subtracted
from each reading. Data were then expressed as mean 6 s.e.m.
signal intensity for each treatment group. Non-specific binding was
calculated in the same way and subtracted from the total to give to
give specific binding. Non-specific binding was found to account
for ,1% of total binding.
Catecholamine quantification. Tissue pieces were sent to
CMN/KC Neurochemistry Core Lab in Vanderbilt University for
HPLC analysis. The brain sections were homogenized in 200–
750 ul of 0.1 M TCA, which contains 10
22 M sodium acetate, 10-
4 M EDTA and 10.5% methanol (pH 3.8) using a tissue
dismembrator (Fisher Scientific). Samples were spun in a
microcentrifuge at 10000 g for 20 minutes. The supernatant was
removed and stored at 280 degrees. The pellet was saved for
protein analysis. Supernatant was then thawed and spun for 20
minutes. Catecholamines were determined by a specific HPLC
assay utilizing an Antec Decade II (oxidation: 0.5) electrochemical
detector operated at 33uC. Samples of the supernatant were
injected using a Water 717+ autosampler onto a Phenomenex
Nucleosil (5u, 100A) C18 HPLC column (15064.60 mm).
Analytes were eluted with a mobile phase consisting of 89.5%
0.1 M TCA, 10
22 M sodium acetate, 10
24 M EDTA and 10.5%
methanol (pH 3.8). Solvent was delivered at 0.8 ml/min using a
Waters 515 HPLC pump. Using this HPLC solvent, analytes were
observed in the following order: DOPAC, dopamine, and HVA.
HPLC control and data acquisition were managed by Waters
Empower software. Total protein for each sample was determined
using the Peirce BCA protein assay. Values of catecholamines are
expressed as ng analyte/mg total protein.
Statistical Analysis
For all statistical comparisons we first used a 1-way ANOVA,
with significance set at P,0.05. If ANOVA was significant, all post-
hoc tests were conducted using Tukey’s Multiple Comparison test.
Software used to conduct statistical analyses and graph all data
was Prism v. 5.02 (GraphPad, La Jolla, CA, USA).
Author Contributions
Conceived and designed the experiments: JBK JMB THJ. Performed the
experiments: JBK THJ MGR PH ME. Analyzed the data: JBK JMB.
Wrote the paper: JBK JMB.
References
1. Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, et al. (2004) Lewy body-
related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63: 742–749.
2. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103: 1661–1668.
3. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, et al. (1997)
a-Synuclein in Lewy bodies. Nature 388: 839–840.
4. Tanji K, Mori F, Mimura J, Itoh K, Kakita A, et al. (2010) Proteinase K-
resistant alpha-synuclein is deposited in presynapses in human Lewy body
disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol.
5. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, et al. (2009) Alpha-
synuclein and polyunsaturated fatty acids promote clathrin-mediated endocy-
tosis and synaptic vesicle recycling. Traffic 10: 218–234.
6. Fortin DL, Nemani VM, Nakamura K, Edwards RH (2010) The behavior of
alpha-synuclein in neurons. Mov Disord 25(Suppl 1): S21–26.
7. Fortin DL, Troyer MD, Nakamura K, Kubo S-i, Anthony MD, et al. (2004)
Lipid Rafts Mediate the Synaptic Localization of a-Synuclein. J Neurosci 24:
6715–6723.
8. Jo E, McLaurin J, Yip CM, St. George-Hyslop P, Fraser PE (2000) a -Synuclein
Membrane Interactions and Lipid Specificity. Journal of Biological Chemistry
275: 34328–34334.
9. Madine J, Hughes E, Doig AJ, Middleton DA (2008) The effects of alpha-
synuclein on phospholipid vesicle integrity: a study using 31P NMR and electron
microscopy. Mol Membr Biol 25: 518–527.
Targeted Overexpression of A53T Alpha-Synuclein
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e1769810. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased
expression of alpha-synuclein reduces neurotransmitter release by inhibiting
synaptic vesicle reclustering after endocytosis. Neuron 65: 66–79.
11. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, et al. (2002) A Role for alpha -
Synuclein in the Regulation of Dopamine Biosynthesis. J Neurosci 22:
3090–3099.
12. Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, et al. (2010) A Pathologic
Cascade Leading to Synaptic Dysfunction in a -Synuclein-Induced Neurode-
generation. J Neurosci 30: 8083–8095.
13. Chung CY, Koprich JB, Siddiqi H, Isacson O (2009) Dynamic changes in
presynaptic and axonal transport proteins combined with striatal neuroin-
flammation precede dopaminergic neuronal loss in a rat model of AAV alpha-
synucleinopathy. J Neurosci 29: 3365–3373.
14. Crews L, Spencer B, Desplats P, Patrick C, Paulino A, et al. (2010) Selective
Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body
Disease and in Models of a -Synucleinopathy. PLoS One 5: e9313.
15. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, et al.
(2008) Dopamine-modified a -synuclein blocks chaperone-mediated autophagy.
The Journal of Clinical Investigation 118: 777–788.
16. Winslow AR, Chen C-W, Corrochano S, Acevedo-Arozena A, Gordon DE,
et al. (2010) a-Synuclein impairs macroautophagy: implications for Parkinson’s
disease. The Journal of Cell Biology 190: 1023–1037.
17. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L (2009) Abberant a-
Synuclein Confers Toxicity to Neurons in Part through Inhibition of
Chaperone-Mediated Autophagy. PLoS One 4: e5515.
18. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al.
(2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s
disease. Lancet 364: 1167–1169.
19. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, et al. (2007) Phenotypic
variation in a large Swedish pedigree due to SNCA duplication and triplication.
Neurology 68: 916–922.
20. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro
mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet
18: 106–108.
21. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997)
Mutation in the alpha-synuclein gene identified in families with Parkinson’s
disease. Science 276: 2045–2047.
22. Zarranz JJ, Alegre J, Go ´mez-Esteban JC, Lezcano E, Ros R, et al. (2004) The
new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body
dementia. Annals of Neurology 55: 164–173.
23. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, et al. (2010) A53T-
Alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal
Synaptic Plasticity in Old Mice. PLoS One 5: e11464.
24. Marie-Francoise C, Sheila F, Farzad M, Bernd M (2008) Strengths and
limitations of genetic mouse models of Parkinson’s disease. Parkinsonism &
related disorders 14: S84–S87.
25. Martin LJ (2007) Transgenic mice with human mutant genes causing
Parkinson’s disease and amyotrophic lateral sclerosis provide common insight
into mechanisms of motor neuron selective vulnerability to degeneration. Rev
Neurosci 18: 115–136.
26. Mendritzki S, Schmidt S, Sczepan T, Zhu XR, Segelcke D, et al. (2010) Spinal
cord pathology in alpha-synuclein transgenic mice. Parkinsons Dis 2010:
375462.
27. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, et al. (2002)
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged
transgenic mice with locomotor deterioration and in human alpha-synucleino-
pathies. J Clin Invest 110: 1429–1439.
28. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, et al.
(2007) Long-term consequences of human alpha-synuclein overexpression in the
primate ventral midbrain. Brain 130: 799–815.
29. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, et al. (2003)
Nigrostriatal a-synucleinopathy induced by viral vector-mediated overexpression
of human a-synuclein: A new primate model of Parkinson’s disease. Proceedings
of the National Academy of Sciences of the United States of America 100:
2884–2889.
30. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, et al. (2002)
Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of
alpha -Synuclein in the Nigrostriatal System. J Neurosci 22: 2780–2791.
31. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia
acquire distinct activation profiles depending on the degree of alpha-synuclein
neuropathology in a rAAV based model of Parkinson’s disease. PLoS One 5:
e8784.
32. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of a-
synuclein in rat substantia nigra results in loss of dopaminergic neurons,
phosphorylation of a-synuclein and activation of caspase-9: resemblance to
pathogenetic changes in Parkinson’s disease. Journal of Neurochemistry 91:
451–461.
33. Maingay M, Romero-Ramos M, Carta M, Kirik D (2006) Ventral tegmental
area dopamine neurons are resistant to human mutant alpha-synuclein
overexpression. Neurobiol Dis 23: 522–532.
34. Lo Bianco C, Ridet J-L, Schneider BL, De ´glon N, Aebischer P (2002) a-
Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based
model of Parkinson’s disease. Proceedings of the National Academy of Sciences
of the United States of America 99: 10813–10818.
35. Koprich J, Johnston T, Reyes M, Sun X, Brotchie J (2010) Expression of human
A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector
produces a rapidly evolving pathology with protein aggregation, dystrophic
neurite architecture and nigrostriatal degeneration with potential to model the
pathology of Parkinson’s disease. Molecular Neurodegeneration 5: 43.
36. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, et al. (2008) The
phosphorylation state of Ser-129 in human a-synuclein determines neurode-
generation in a rat model of Parkinson disease. Proceedings of the National
Academy of Sciences 105: 763–768.
37. Garcia- Reitbo ¨ck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, et al. (2010)
SNARE protein redistribution and synaptic failure in a transgenic mouse model
of Parkinson’s disease. Brain 133: 2032–2044.
38. Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD, et al. (2008)
Increased amphetamine-induced hyperactivity and reward in mice overexpress-
ing the dopamine transporter. Proceedings of the National Academy of Sciences
105: 4405–4410.
39. George Paxinos CW (1998) The rat brain in sterotaxic coordinates. San Diego:
Academic Press.
40. Hauck B, Chen L, Xiao W (2003) Generation and characterization of chimeric
recombinant AAV vectors. Mol Ther 7: 419–425.
41. Ian Q, Wishaw BK, eds (2005) The behaviour of the laboratory rat: a handbook
with tests. First ed. New York: Oxford University Press. 499 p.
Targeted Overexpression of A53T Alpha-Synuclein
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17698